Merrion and Rebel Pharmaceuticals Sign Drug Feasibility and Option Agreement

被引：0

|

作者：

不详

机构：

来源：

BIOPHARM INTERNATIONAL | 2011年 / 24卷 / 01期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

收藏

页码：13 / 13

页数：1

相关论文

共 7 条

[1] Pharmaceuticals - Xenova in drug agreement
不详
EUROPEAN CHEMICAL NEWS, 1997, 67 (1768): : 56 - 56
[2] Genaissance Pharmaceuticals and AstraZeneca sign a genomics agreement
不详
PHARMACOGENOMICS, 2002, 3 (01) : 4 - 4
[3] Arris and Sequana Therapeutics sign merger agreement to become AxyS Pharmaceuticals
Stirling, J
GENETIC ENGINEERING NEWS, 1997, 17 (20): : 1 - &
[4] Pharmaceuticals - Doubt over benefits of WTO drug agreement for poorer nations
不详
CHEMISTRY & INDUSTRY, 2003, (18) : 6 - 6
[5] China, Russia and Republic of Korea Sign Agreement on Feasibility Study of Natural Gas Project
China Oil & Gas, 2000, (04) : 59 - 59
[6] Airpharma and Britannia sign licensing agreement for asthma drug AP-0016
不详
DRUG NEWS & PERSPECTIVES, 2004, 17 (09) : 605 - 605
[7] Compound GW506U78 has high single-drug activity and good feasibility in heavily pretreated relapsed T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) and offers the option for cure with stem cell transplantation (SCT).
Goekbuget, N
Arnold, R
Atta, J
Brück, P
Hermann, S
Horst, H
Kondakci, M
Kotthoff, R
Ottmann, O
Raff, T
Ratei, R
Schmid, M
Stadler, M
Hoelzer, D
BLOOD, 2005, 106 (11) : 47A - 48A